Daily Low-Dose Tadalafil & Cognition: What the Evidence Shows
Tadalafil is a PDE5 inhibitor: it raises cGMP and relaxes vascular smooth muscle. It is FDA-approved for erectile dysfunction, benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension. Low daily doses (2.5β5 mg) are also discussed for brain blood flow and cognition, cardiovascular health and exercise. This page sets out what the cited research found, at which doses, and what is still untested: the only human trial of tadalafil on cognition cited here, at 20 mg daily for 3 months, found no benefit, and no cited trial has tested cognition at 2.5β5 mg.
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
Four Proposed Mechanisms
Four mechanisms are proposed for tadalafil beyond erectile dysfunction. Here is each one, and how far the human data actually go.
Cerebral Blood Flow
PDE5 mRNA has been detected in mouse and human brain tissue GarcΓa-Barroso 2013 (PMID 22776546). When tadalafil inhibits PDE5, cGMP accumulates β smooth muscle relaxation β vasodilation. Human brain blood flow results are mixed: a single 20 mg dose gave a non-significant rise in subcortical blood flow in older adults with small vessel disease PASTIS 2022 (PMID 35135037), while 3 months of 20 mg daily raised whole-brain blood flow by 3.3 ml/100 g/min over placebo (from a baseline of 25.4) in a small-vessel-disease MRI sub-study ETLAS-2 2026 (PMID 42643719). No trial cited here has tested brain blood flow at 2.5β5 mg.
Stimulant Counterbalance (Untested)
Some biohackers pair tadalafil with modafinil, caffeine or amphetamines on the theory that a vasodilator offsets stimulant-related vasoconstriction. That is a hypothesis, not a finding: none of the research cited on this page tested tadalafil with any stimulant, so there is no evidence on whether the combination works or is safe. Tadalafil lowers blood pressure Curr Vasc Pharmacol 2022 (PMID 36043781), so any combination is one to clear with a physician first.
Cardiovascular Effects
Tadalafil is FDA-approved as Adcirca for pulmonary arterial hypertension, but at 40 mg once daily: in the PHIRST trial only the 40 mg dose significantly improved 6-minute walk distance, and the 2.5 mg arm did not Circulation 2009 (PMID 19470885). On endothelial function the cited trials are null: low-dose tadalafil matched placebo on flow-mediated dilation in men with ED Sex Med 2019 (PMID 30638829). A 2.5β5 mg daily dose has not been shown to improve endothelial function.
Neuroprotection
In a mouse model of Alzheimer's disease, GarcΓa-Barroso et al. showed tadalafil crosses the bloodβbrain barrier, and 10 weeks of treatment improved water-maze performance and reduced hippocampal tau phosphorylation without changing amyloid burden Neuropharmacology 2013 (PMID 22776546). Human data are thin. The often-cited Shim et al. 2014 daily low-dose trial in ED patients tested udenafil, a different PDE5 inhibitor, not tadalafil Int J Impot Res 2014 (PMID 24285284). In the ETLAS-2 trial, 3 months of tadalafil 20 mg daily did not improve cognition versus placebo in small vessel disease Cereb Circ Cogn Behav 2025 (PMID 41332889).
What the Studies Show
The cognitive research on tadalafil is mostly preclinical, and the few human trials so far are small and mostly null. Here's an honest breakdown of what we know.
Doses Used in the Research
The human tadalafil trials cited on this page used doses from 2.5 mg (the lowest PHIRST arm) to 40 mg daily. The brain blood flow and cognition trials used 20 mg (a single dose in PASTIS, daily for 3 months in ETLAS-2); 5 mg daily is the BPH dose. This section describes what was studied, not a dosing instruction.
Approved vs. Off-Label Uses
Tadalafil has three FDA-approved uses. The off-label uses below are proposed, not established; the evidence for each is noted.
Tadalafil vs. Sildenafil for Daily Use
For once-daily use, the differences the cited sources document are pharmacokinetic. Nothing in this table is evidence of a cognitive effect for either drug.
| Property | Tadalafil (Cialis) | Sildenafil (Viagra) |
|---|---|---|
| Half-Life | ~17.5 hours (PMID 16487221) | Not reported in the sources cited here |
| Daily Dosing Viability | Yes, 2.5β5mg daily | Not covered by the sources cited here |
| Food Interaction | Negligible (PMID 16487221) | Food slows absorption, delaying peak by ~1 h (PMID 11879254) |
| Once-Daily Low-Dose RCT Data | Yes: 5mg daily in BPH (PMID 21871706) | Not covered by the sources cited here |
| FDA Approval for PAH | Yes (as Adcirca) | Yes (as Revatio) |
Cardiovascular & Endothelial Health
Tadalafil's vascular effects have also been studied outside the brain. The strongest human evidence is in pulmonary arterial hypertension, at 40 mg once daily, well above 2.5β5 mg. Peripheral endothelial-function results are mostly null.
Exercise Performance & Recovery
If vasodilation increases oxygen and nutrient delivery to working tissue, the obvious question is whether that translates to exercise. The honest answer: clearly in pulmonary arterial hypertension at 40 mg; the research cited here includes no trials in healthy athletes.
Exercise Capacity in PAH
The strongest performance signal comes from disease populations. In PHIRST, tadalafil 40 mg once daily improved the 6-minute walk distance by a placebo-corrected 33 metres in pulmonary arterial hypertension, a real, measured increase in exercise tolerance. Only the 40 mg dose reached statistical significance. Circulation 2009 (PMID 19470885).
Muscle Oxygen Delivery
The rationale some athletes cite is that a vasodilator could raise blood flow to working muscle. None of the research cited on this page measured muscle blood flow or exercise performance in healthy people, so for them this remains a hypothesis.
Recovery Rationale
Greater perfusion theoretically aids nutrient clearance and delivery during recovery, and the ~17.5-hour half-life (PMID 16487221) means once-daily dosing keeps levels steady across back-to-back training days. The recovery angle is a hypothesis, not established by controlled human recovery trials.
Benign Prostatic Hyperplasia (BPH)
This is not off-label or speculative: tadalafil 5 mg once daily is FDA-approved for the signs and symptoms of benign prostatic hyperplasia. It is the clearest randomized evidence for a daily 5 mg dose among the studies cited here, and that evidence is for urinary symptoms, not cognition.
What We Know & What We Don't
- Tadalafil inhibits PDE5 and increases cGMP, the final mediator of the nitric oxide pathway (PMID 19470885)
- PDE5 mRNA is present in mouse and human brain; tadalafil crosses the bloodβbrain barrier in mice (PMID 22776546)
- ~17.5-hour mean half-life; once-daily dosing reaches steady state by day 5 (PMID 16487221)
- FDA-approved for BPH β daily 5mg cuts IPSS ~2 points vs placebo (PMID 21871706)
- FDA-approved for PAH β 40mg daily added +33m 6-min walk in PHIRST; the 2.5mg arm was not significant (PMID 19470885)
- 3 months of 20mg daily raised whole-brain blood flow vs placebo in small vessel disease (PMID 42643719)
- Mouse Alzheimer's model: 10 weeks of tadalafil improved water-maze memory and lowered tau phosphorylation (PMID 22776546)
- A single 20mg dose lowered blood pressure and pulse-wave velocity in grade-1 obesity (acute effect; PMID 36043781)
- Large-scale human RCTs for cognitive enhancement; a 3-month RCT at 20mg daily found no cognitive difference vs placebo (PMID 41332889)
- Long-term safety data for daily use beyond 5 years
- Any brain blood flow or cognitive data at 2.5β5mg daily
- Any interaction or efficacy data for tadalafil combined with modafinil, other stimulants or nootropics
- Head-to-head cognitive data vs. sildenafil at equivalent doses
- Performance data in healthy young adults (most studies in older/patient populations)
- Any endothelial-function (FMD) benefit β the cited trials found none vs placebo (PMID 30638829, 36043781)
- Placebo-controlled confirmation of the endothelial progenitor cell rise seen with 3 months of on-demand 20mg in one small before-and-after study of 30 men with ED + metabolic syndrome, no placebo arm (PMID 21804479)
- Proven ergogenic effect in healthy, well-trained athletes (signal is in disease populations)
- Effect on urinary flow rate (Qmax) in BPH is modest and variable β it eases symptoms, not prostate size
Recommended Products
Monitoring tools, plus two nitric-oxide-related supplements. None were tested with tadalafil in the research cited here; ask a physician before combining anything with a PDE5 inhibitor.
Affiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.